Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, randomized, crossover phase 1 study to determine safety, tolerability, and pharmacokinetics of Zolmitriptan PassPort for treatment of Acute Migraine

Next Previous
Trial Profile

An open-label, randomized, crossover phase 1 study to determine safety, tolerability, and pharmacokinetics of Zolmitriptan PassPort for treatment of Acute Migraine

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 29 Mar 2024 According to PassPort Technologies media release, Part B of this study is currently underway, will evaluate the transdermal administration of a single dose at alternative sites, the subject's abdomen and upper thigh. The final results will be available to the public in Q3 2024.
  • 29 Mar 2024 Interim results from phase 1 (Part A) clinical trial presented in a Passport Technologies Media Release.
  • 27 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top